Nipro Corporation
8086.T · Tokyo Stock Exchange · JPY
1.331,00JPY
−67,50 (−4,83 %)Stand 11. Nov., 6:30
Kennzahlen
- Eröffnung
- 1.360,00
- Vortag
- 1.398,50
- Tagesspanne
- 1.318,50 – 1.362,50
- 52 Wochen
- 1.292,50 – 1.760,50
- Volumen
- 1,6 Mio.
- Ø Volumen
- 709.872
- Börsenwert
- 217,08 Mrd. ¥
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- -0,0
- Nächste Zahlen
- –
Finanzen
| JPY | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 660,54 Mrd. | 644,59 Mrd. | 586,79 Mrd. | 545,2 Mrd. | 494,79 Mrd. |
| Herstellungskosten | 452,26 Mrd. | 450,93 Mrd. | 412,81 Mrd. | 379,3 Mrd. | 342,95 Mrd. |
| Bruttogewinn | 208,28 Mrd. | 193,66 Mrd. | 173,98 Mrd. | 165,9 Mrd. | 151,84 Mrd. |
| Forschung und Entwicklung | 0 | 21,67 Mrd. | 20,85 Mrd. | 19,67 Mrd. | 18,73 Mrd. |
| Vertrieb und Verwaltung | 170,66 Mrd. | 145,39 Mrd. | 130,8 Mrd. | 128,5 Mrd. | 109,22 Mrd. |
| Operatives Ergebnis | 37,63 Mrd. | 26,6 Mrd. | 22,34 Mrd. | 17,73 Mrd. | 23,88 Mrd. |
| EBITDA | 102,99 Mrd. | 92,58 Mrd. | 84,62 Mrd. | 70,02 Mrd. | 73,6 Mrd. |
| Nettogewinn | 13,5 Mrd. | 5,11 Mrd. | 11,11 Mrd. | 4,58 Mrd. | 13,46 Mrd. |
| Gewinn je Aktie (verwässert) | 73,36 | 27,78 | 60,35 | 24,85 | 77,42 |
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
- CEO
- Yoshihiko Sano
- Mitarbeitende
- 38.593
- Hauptsitz
- Settsu, OS, JP
- Sektor
- Healthcare
- Branche
- Medical - Instruments & Supplies
- Börsengang
- 1. Jan. 2001
- Website
- nipro.co.jp
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.